Janet M. Johnston

Janet M. Johnston

Auto-generated profile, based on publicly available information

Janet M. Johnston

Liver Disease and Hepatitis Program, Alaska Native Tribal Health Consortium, Anchorage, Alaska, USA

Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 September 2001 in Neurology
Verified
Journal Article
Closed access
PDF file
VCV. Chandra
V. Chandra
RPR. Pandav
R. Pandav
HDH.H. Dodge
H.H. Dodge
JJJ.M. Johnston
J.M. Johnston
SBS.H. Belle
S.H. Belle
MGM. Ganguli
M. Ganguli
Objective: To determine overall and age-specific incidence rates of AD in a rural, population-based cohort in Ballabgarh, India, and to compare them with those of a reference US population in the Monongahela Valley of Pennsylvania. Methods: A 2-year, prospective, epidemiologic study of subjects aged ≥55 years utilizing repeated cognitive and functional ability screening, followed by standardized clinical evaluation using the Diagnostic and Statistical Manual of Mental Disorders, 4th edition, and the National Institute of Neurological and Communicative Disorders and Stroke–Alzheimer’s Disease and Related Disorders Association criteria for the diagnosis, and the Clinical Dementia Rating scale for the staging, of dementia and AD. Results: Incidence rates per 1000 person–years for AD with CDR ≥0.5 were 3.24 (95% CI: 1.48–6.14) for those aged ≥65 years and 1.74 (95% CI: 0.84–3.20) for those aged ≥55 years. Standardized against the age distribution of the 1990 US Census, the overall incidence rate in those aged ≥65 years was 4.7 per 1000 person–years, substantially lower than the corresponding rate of 17.5 per 1000 person–years in the Monongahela Valley. Conclusion: These are the first AD incidence rates to be reported from the Indian subcontinent, and they appear to be among the lowest ever reported. However, the relatively short duration of follow-up, cultural factors, and other potential confounders suggest caution in interpreting this finding.

1 June 2008 in Clinical Chemistry
Verified
Journal Article
Closed access
PDF file
AKAlyson Kelley-Hedgepeth
Alyson Kelley-Hedgepeth
DLDonald M Lloyd-Jones
Donald M Lloyd-Jones
ACAlicia Colvin
Alicia Colvin
KMKaren A Matthews
Karen A Matthews
JJJanet Johnston
Janet Johnston
FIfor the SWAN Investigators
for the SWAN Investigators
Background: Limited data exist regarding the ethnic differences in C-reactive protein (CRP) concentrations, an inflammatory marker associated with risk of cardiovascular disease (CVD). We hypothesized that known CVD risk factors, including anthropometric characteristics, would explain much of the observed ethnic variation in CRP. Methods: We performed a cross-sectional analysis of 3154 women, without known CVD and not receiving hormone therapy, enrolled in the Study of Women’s Health Across the Nation (SWAN), a multiethnic prospective study of pre- and perimenopausal women. Results: The study population was 47.4% white, 27.7% African-American, 8.5% Hispanic, 7.7% Chinese, and 8.6% Japanese; mean age was 46.2 years. African-American women had the highest median CRP concentrations (3.2 mg/L), followed by Hispanic (2.3 mg/L), white (1.5 mg/L), Chinese (0.7 mg/L), and Japanese (0.5 mg/L) women (all pairwise P < 0.001 compared with white women). Body mass index (BMI) markedly attenuated the association between ethnicity and CRP. After adjusting for age, socioeconomic status, BMI, and other risk factors, African-American ethnicity was associated with CRP concentrations >3 mg/L (odds ratio 1.37, 95% CI 1.07–1.75), whereas Chinese and Japanese ethnicities were inversely related (0.58, 0.35–0.95, and 0.43, 0.26–0.72, respectively). Conclusions: Modifiable risk factors, particularly BMI, account for much but not all of the ethnic differences in CRP concentrations. Further study is needed of these ethnic differences and their implications for the use of CRP in CVD risk prediction.

1 April 2006 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
MSMaryFran R. Sowers
MaryFran R. Sowers
MJMary Jannausch
Mary Jannausch
DMDaniel McConnell
Daniel McConnell
RLRoderick Little
Roderick Little
GGGail A. Greendale
Gail A. Greendale
BEBruce Ettinger
Bruce Ettinger
OBJECTIVE AND CONTEXT: Our objective was to examine predictability of reproductive hormone concentrations for bone mineral density (BMD) loss during the menopausal transition. We conducted a longitudinal (five annual examinations), multiple-site (n = 5) cohort study, the Study of Women's Health Across the Nation (SWAN). Participants included, at baseline, 2311 premenopausal or early perimenopausal African-American, Caucasian, Chinese, and Japanese women. We assessed annual dual-energy x-ray absorptiometry lumbar spine and total hip BMD measures, with endogenous estradiol (E2), FSH, androgens, and self-reported menstrual bleeding patterns. Over the 4-yr period, lumbar spine BMD loss was 5.6% in natural postmenopause, 3.9% in surgical postmenopause, or 3.2% in late perimenopause. Baseline FSH concentrations, subsequent FSH levels, and their interaction predicted 4-yr BMD loss. If baseline FSH was less than 25 mIU/ml, higher follow-up FSH (>70 mIU/ml) predicted a 4-yr spine BMD loss of -0.05 g/cm(2). If baseline FSH values were more than 35-45 mIU/ml, lower follow-up FSH (i.e. 40-50 mIU/ml) predicted a -0.05 g/cm(2) 4-yr spine BMD loss. Charts show amounts of predicted BMD losses with combinations of baseline FSH values and FSH levels over time. E2 concentrations less than 35 pg/ml were associated with lower BMD, but annual E2 measures and changes did not predict BMD loss. Testosterone, free androgen index, and dehydroepiandrosterone sulfate concentrations were not significantly associated with BMD loss. Spine and hip BMD losses during the menopause transition were most strongly related to the interaction between initial FSH levels and longitudinal FSH changes and not to E2 or androgen levels or changes.

1 May 2002 in JACC
Verified
Journal Article
Closed access
AJAlice K. K. Jacobs
Alice K. K. Jacobs
JJJanet M Johnston
Janet M Johnston
AHAmelia Haviland
Amelia Haviland
MBMaria Mori Mori Brooks
Maria Mori Mori Brooks
SKSheryl F Kelsey
Sheryl F Kelsey
KDKatherine M Detre
Katherine M Detre

28 May 2014 in Arthritis & Rheumatology
Verified
Journal Article
Open access
PDF file
EFElizabeth D. Ferucci
Elizabeth D. Ferucci
JJJanet M. Johnston
Janet M. Johnston
JGJasmine R. Gaddy
Jasmine R. Gaddy
LSLisa Sumner
Lisa Sumner
JPJames O. Posever
James O. Posever
CHCharles G. Helmick
Charles G. Helmick
Objective: Few studies have investigated the epidemiology of systemic lupus erythematosus (SLE) in American Indian and Alaska Native populations. The objective of this study was to determine the prevalence and incidence of SLE in the Indian Health Service (IHS) active clinical population in 3 regions of the US.Methods: For this population‐based registry within the IHS, the denominator consisted of individuals in the IHS active clinical population in 2007, 2008, and/or 2009 and residing in a community in 1 of 3 specified regions. Potential SLE cases were identified based on the presence of a diagnostic code for SLE or related disorder in the IHS National Data Warehouse. Detailed medical record abstraction was performed for each potential case. The primary case definition was documentation in the medical record of ≥4 of the revised American College of Rheumatology criteria for the classification of SLE. Prevalence was calculated for 2007, and the mean annual incidence was calculated for the years 2007 through 2009.Results: The age‐adjusted prevalence and incidence of SLE according to the primary definition were 178 per 100,000 person‐years (95% confidence interval [95% CI] 157–200) and 7.4 per 100,000 person‐years (95% CI 5.1–10.4). Among women, the age‐adjusted prevalence was 271, and the age‐adjusted incidence was 10.4. The prevalence was highest in women ages 50–59 years and in the Phoenix Area IHS.Conclusion: The first population‐based lupus registry in the US American Indian and Alaska Native population has demonstrated that the prevalence and incidence of SLE are high. Our estimates are as high as or higher than the rates reported in the US black population.

24 September 2002 in Circulation
Verified
Journal Article
Closed access
PDF file
VSV.S. Srinivas
V.S. Srinivas
MBMaria Mori Mori Brooks
Maria Mori Mori Brooks
KDKatherine M. Detre
Katherine M. Detre
SKSpencer B. King
Spencer B. King
AJAlice K. K. Jacobs
Alice K. K. Jacobs
DWDavid O. Williams
David O. Williams
Background— This investigation compares the results of contemporary percutaneous coronary intervention (PCI) with standard balloon angioplasty among patients with multivessel coronary disease. Patients having balloon angioplasty in the Bypass Angioplasty Revascularization Investigation (BARI) and those within the Dynamic Registry meeting BARI eligibility criteria were studied. Methods and Results— Clinical features and in-hospital and 1-year outcomes of 857 BARI-eligible patients in the Dynamic Registry (contemporary PCI) were compared with the 904 randomized patients who underwent percutaneous transluminal coronary angioplasty in BARI. Compared with BARI patients, Registry patients had fewer lesions attempted (1.53 versus 2.56, P =0.001), more frequent single-vessel PCI (76% versus 33%, P <0.001), greater use of intracoronary stents (76% versus 1%, P <0.001), and GP IIb/IIIa receptor antagonist (24% versus 0%, P <0.001). Angiographic success was achieved more often among Registry patients (91% versus 72%, P <0.001), whereas abrupt closure (1.5% versus 9.5%, P <0.001) and in-hospital coronary artery bypass graft (CABG) (1.9% versus 10.2%, P <0.001) and myocardial infarction (0.8% versus 2.1%, P =0.025) were less common. No differences were observed in either in-hospital or 1-year death, but 1-year death/myocardial infarction was lower in the Registry. Registry patients had lower 1-year rates of subsequent CABG (8.6% versus 22.7%, P <0.001) and PCI (12.4% versus 22.5%, P <0.001). By multivariate analysis, contemporary PCI was independently associated with reduced risk for in-hospital CABG, 1-year CABG, and 1-year PCI. Conclusions— Among patients with multivessel disease, contemporary PCI resulted in safer and more durable revascularization. These results support the role of PCI for selected patients with multivessel coronary artery disease.